MedPage Today) -- SAN FRANCISCO -- A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of plasma concentrations compared with twice-yearly subcutaneous lenacapavir for HIV pre...
Market Touch Signal · Finland · international digital desk
+358 400 512311
info@market-touch.org